Clinical Trials
22 trialsClinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
BELAMI
Centre Hospitalier Universitaire de Saint Etienne
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
FLOW
The First Affiliated Hospital of Soochow University
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Chinese PLA General Hospital
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
University of Miami
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California, Davis
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Chinese PLA General Hospital
STIR
Medical College of Wisconsin
CAR-T for NHL
National University of Malaysia
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
SBRT Plus vNKT for Pancreatic Cancer
Changhai Hospital
273
Brown University
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The First Affiliated Hospital of Soochow University
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University